G protein-coupled receptor (GPCR) signaling, mediated by hetero-trimeric G proteins, can be differentially controlled by agonists. At a molecular level, this is thought to occur principally via stabilization of distinct receptor conformations by individual ligands. These distinct conformations control subsequent recruitment of transducer and effector proteins. Here, we report that ligand efficacy at the calcitonin GPCR (CTR) is also correlated with ligand-dependent alterations to G protein conformation. We observe ligand-dependent differences in the sensitivity of the G protein ternary complex to disruption by GTP, due to conformational differences in the receptor-bound G protein hetero-trimer. This results in divergent agonist-dependent receptor-residency times for the hetero-trimeric G protein and different accumulation rates for downstream second messengers. This study demonstrates that factors influencing efficacy extend beyond receptor conformation(s) and expands understanding of the molecular basis for how G proteins control/influence efficacy. This has important implications for the mechanisms that underlie ligand-mediated biased agonism.
In Brief
Ligand binding to a G protein-coupled receptor not only affects the receptor conformation, but also modulates the bound G protein to shape downstream signaling.
SUMMARY
G protein-coupled receptor (GPCR) signaling, mediated by hetero-trimeric G proteins, can be differentially controlled by agonists. At a molecular level, this is thought to occur principally via stabilization of distinct receptor conformations by individual ligands. These distinct conformations control subsequent recruitment of transducer and effector proteins. Here, we report that ligand efficacy at the calcitonin GPCR (CTR) is also correlated with ligand-dependent alterations to G protein conformation. We observe ligand-dependent differences in the sensitivity of the G protein ternary complex to disruption by GTP, due to conformational differences in the receptor-bound G protein hetero-trimer. This results in divergent agonist-dependent receptor-residency times for the hetero-trimeric G protein and different accumulation rates for downstream second messengers. This study demonstrates that factors influencing efficacy extend beyond receptor conformation(s) and expands understanding of the molecular basis for how G proteins control/influence efficacy. This has important implications for the mechanisms that underlie ligand-mediated biased agonism.
INTRODUCTION
G protein-coupled receptors (GPCRs) are the largest family of cell-surface receptors, sensing a diverse array of stimuli from the extracellular environment and transmitting these signals to evoke cellular responses. This fundamental function is encapsulated by the concept of efficacy, which relates receptor occupancy by an agonist to the magnitude of the cellular response (Kenakin, 2002) . The existence of ligands displaying different efficacies and, in particular, ligands displaying preferential signaling to different effectors has led to a model in which GPCRs can adopt multiple active states (Kenakin, 2002; Kim et al., 2013) . Such ligand-directed signaling bias (biased agonism) is now an important focus in drug discovery (Kenakin and Christopoulos, 2013) , but there are limited data addressing the mechanisms by which such differential efficacy occurs.
GPCRs are highly dynamic proteins that rapidly sample a range of both active and inactive conformations (Deupi and Kobilka, 2010) . Activation of GPCRs occurs due to changes in the proportion of time the receptor spends in one or more active states upon agonist binding. This is due to a relative decrease in the energy state of the active receptor in the receptor:agonist complex (Deupi and Kobilka, 2010) . The principal driver for differential efficacy is thought to be distinct receptor conformations stabilized by different ligands. For example, ligands with distinct efficacies show divergent sampling of conformational space for the b 2 -adrenoceptor (ADRB2) (Nygaard et al., 2013) , the ghrelin (GHSR) (Mary et al., 2012) , serotonin (HTR2B) (Wacker et al., 2013) , and the glucagon-like peptide 1 (GLP1R) receptors (Wootten et al., 2013) . These divergent active conformations are thought to have different affinities for their cognate G protein hetero-trimer, providing a mechanism by which agonists could achieve differential receptor activation.
Early work by Seifert et al. (1999 Seifert et al. ( , 2001 , however, provided the first hint that the ligand-receptor complex may also distinctly affect G protein conformations, and this has been supported by G protein fluorescence resonance energy transfer (FRET) in the presence of partial versus full agonists (Nikolaev et al., 2006) . Additionally, recent work by Goricanec et al. (2016) has shown that the Ga subunit itself is highly dynamic, sampling a number of conformations in both GDP-bound and nucleotidefree states. Nonetheless, these data on differences in receptor:G protein complexes have principally been interpreted as differences in G protein recruitment to the receptor due to distinct ligand-receptor conformations. At the most basic level, the role of the GPCR is as a guanine nucleotide exchange factor (GEF), responsible for stimulating the exchange of GDP for GTP at the G a subunit of hetero-trimeric G proteins resulting in their activation. By extension therefore, the formation of an agonist:receptor complex potentiates the receptor's GEF activity; thus, the agonist is a positive allosteric modulator of the GPCRs GEF activity. As such, we posit that efficacy differences must translate into differential GEF activity of the GPCR. This could be due to differences in GPCR affinity for G protein but potentially also due to agonist-dependent conformational differences in G proteins, resulting in changes to nucleotide exchange rate.
The human calcitonin receptor (CTR) is the most ancient of class B GPCRs (Fredriksson et al., 2003; Nag et al., 2007) . It is widely expressed in adults and during development and has complex roles in bone metabolism, brain function, cell cycle, and cancer (Clarke et al., 2015; Davey and Findlay, 2013; Venkatanarayan et al., 2015; Yamaguchi et al., 2015) , including an antiapoptotic role in osteoclasts (Selander et al., 1996) and thymic lymphomas (Venkatanarayan et al., 2015) . CTR is a clinical target for the treatment of multiple diseases including Paget's disease, osteoporosis, and hypercalcemia of malignancy, with both human and salmon calcitonins (hCT and sCT, respectively) used clinically. These two peptides display distinct potency/efficacy for guanine nucleotide-binding protein G(s) subunit alpha isoforms short (G as )-mediated cyclic AMP (cAMP) production, in a cell-dependent manner (Andreassen et al., 2014; Hilton et al., 2000; Kuestner et al., 1994) . We sought to understand the mechanistic basis of the differential efficacy displayed by hCT and sCT at the CTR. Here, we demonstrate that variations in cellular efficacy are correlated with agonist-dependent, conformational differences promoted in G proteins. This current work extends the concept of conformational selection at the level of the agonist: receptor complex to one that includes conformation selection at the level of the agonist:receptor:G protein complex.
RESULTS

CTR Ligands Have Distinct Potencies for G Protein Recruitment
The CTR is most strongly coupled to the stimulatory G alpha subunit, G as , upstream of adenylate-cyclase-mediated cAMP production. To define the cellular efficacy of hCT and sCT, we performed cAMP accumulation and ligand binding assays ( Figures 1A, 1B , and S1A-S1E). Consistent with previous publications (Andreassen et al., 2014; Hilton et al., 2000) , in cAMP accumulation assays ( Figure 1A ) the concentration response curves to both ligands were not significantly different, with similar EC 50 and E max values. We performed competition binding on whole cells and isolated plasma membranes to determine the affinity constants for both ligands (Figures 1B and S1A-S1E). sCT had high affinity for the receptor that could be defined by a single binding constant. In contrast, hCT had lower affinity with two discernible affinity states, both of which are lower than that of sCT. Similar to certain chemokine GPCRs (Di Salvo et al., 2000) , and, in contrast to GPCRs for small molecules such as biogenic amines and acetylcholine (Brodde et al., 1982; Kellar et al., 1985) , we found that the distribution of CTR affinity states was unaffected by the non-hydrolysable GTP analog GppNHp (Figures S1D and S1E), suggesting that binding of G protein to the CTR is not a major driver of conformational selection for this receptor, unlike recent data for the b 2 adrenergic receptor (DeVree et al., 2016) .
The observed affinity represents a composite of all the interchangeable affinity states of the receptor at equilibrium (Liu et al., 2012; Nygaard et al., 2013) . To define the particular affinity state(s) associated with the ternary complex containing native G as , we explicitly identified this complex using native PAGE (Wittig et al., 2006 (Wittig et al., , 2007 (Figures 1C, 1D , S2, and 2B). This allowed us to directly establish concentration-response curves for agonist promoted recruitment of G as protein ( Figures 1C and  1D ). Similar to measures of ligand affinity ( Figure 1B ), sCT had an $10-fold greater potency over hCT for promotion of G as recruitment ( Figure 1D ). This suggests that the equivalent efficacy of the ligands in cAMP accumulation ( Figure 1A ) was not purely driven by efficiency of G protein recruitment (Figures 1A versus 1D) . To better understand the nature of the agonist: receptor:G protein (ternary) complex, the relative stoichiometry of receptor and G protein was defined by using Fab fragments to induce discrete mobility shifts (Figures 2A-2C) . The presence of a single shift in mobility of the ternary complex with increasing (A) cAMP accumulation assay in COS-7 cells stably expressing CTR with cells stimulated for 30 min in the presence of IBMX with the indicated concentrations of hCT or sCT. Both agonist response curves are best described by a biphasic curve (F test, p < 0.0001) with a common fit (F test, p = 0.979, n = 8, each n in triplicate with different drug dilutions on different days, data are mean ± SEM) with log EC 50 values of À11.00 ± 0.18 and À8.67 ± 0.12. (B) Whole-cell competition ligand binding in which cells were incubated overnight at 4 C with 10 nM sCT8-32:AF568 (antagonist, affinity defined by saturation binding; Figure S1B ) in the presence of the indicated concentrations of cold competing agonist. sCT competition is best described by a single-site fit with a log Ki of À9.10 ± 0.07; hCT competition fits to a two-site model (F test, p = 0.0007) with log Ki values of À7.30 ± 0.31 and À8.64 ± 0.26 (n = 6, each n in triplicate with different drug dilutions on different days, data are mean ± SEM).
(C and D) Plasma-membrane preparations from COS-7 cells expressing CTR were treated with various concentrations of agonists prior to solubilization in Lauryl Maltose Neopentyl Glycol (MNG)/Cholesterol Hemisuccinate (CHS) and separation on a 6%-11% clear native page and transfer. The ternary complex was identified by probing for mobility shift in G as with a representative blot (from n = 4, each n with different plasma-membrane preparations and different drug dilutions on different days) shown in (C) and quantified densitometry (Fiji) shown in (D) (data are mean ± SEM). Estimated log EC 50 values for ternary complex formation are À8.58 ± 0.13 for hCT and À9.80 ± 0.08 for sCT (F test, p value for different EC 50 of <0.0001). See also Figure S1 .
concentrations of Fab against the receptor indicated a monomeric receptor in the G protein-bound complex ( Figure 2A ). In contrast, in the absence of agonist, the two different receptor bands undergo either single or double Fab-induced mobility shifts, suggesting both monomeric and dimeric receptor species ( Figure 2C ). Taken together with the loss of dimeric receptor with increasing G protein interaction ( Figure 2B ), this indicated that the ligand-responsive receptor species is dimeric, but, upon G protein binding, the dimeric interface weakens and G protein activation occurs in cis ( Figure 2A and compare with Figure S2 ). This is consistent with a proposed model for b1 adrenergic receptor activation where the dimer interface partially overlaps the G protein-binding interface (Huang et al., 2013) and is depicted in the cartoon in Figure 2H . The apparent mobility observed for the ternary complex by native PAGE was lower than predicted from the molecular weight of the individual components. As an additional confirmation, the same relative mobility ($440 kDa) and stoichiometry (1:1:1:1 [molecular weight divided by intensity]) of the ternary complex was observed when expressed and purified from insect cells (Figures 2D and 2E) .
CT Ligands Promote Distinct G Protein Conformations Linked to Guanine Nucleotide Exchange and Signaling
To understand how G as activation might differ between hCT and sCT, we defined the transduction mechanism of the All n numbers for all experiments were performed with different (plasma) membrane preparations on different days. (A) A representative mobility shift assay (n = 3) using an Fab directed against the N-terminal epitope tag of CTR shows that the ternary complex contains only one CTR protomer, which is shown in cartoon with CTR in blue.
(B) A representative two-color blot (n = 4) of ligand-dependent transition of CTR (yellow) and G as (magenta) to the ternary complex indicating the mobility of CTR increases as it transitions to the ternary complex, consistent with a transition from the dimeric complex ( Figure S2 ). (C) Plasma-membrane preparations from COS-7 cells expressing CTR were incubated with increasing amounts of anti-CTR C-terminal Fab (1H10, IgG 2a ) during solubilization in digitonin at 6 g/g for 50 min at 4 C, separation on a 4%-13.5% blue native page and transfer. Solubilization in digitonin followed by blue native PAGE preserves the 1H10 Fab interaction with CTR but results in relatively poor solubilization of CTR. The shift in CTR mobility was identified using anti-cMyc (9E10, IgG 1 ) followed by an isotype-specific secondary; the quantified densitometry was fitted to Gaussian distributions indicating a single shift in the lower-molecular-weight complex and two shifts in the higher molecular weight complex (n = 3).
(D and E) (D) A representative size exclusion chromatography trace comparing the relative mobility of insect cell-expressed and purified sCT/CTR/G as /G b /G g ternary complex with that of a known standard, ferritin, with the purified material shown on a Coomassie-stained gel in (E) and quantified by densitometry supportive of a 1:1:1:1 stoichiometry (representative of more than five experiments).
(F) Extensively washed plasma-membrane preparations from COS-7 cells stably expressing CTR were treated with various concentrations of GTP in the presence of (saturating) equi-occupant concentrations of agonist prior to solubilization and separation on a 6%-11% native page and transfer.
(G) The ternary complex was identified by probing for mobility shift in G as with a representative blot (from n = 3) shown in (G) and quantified densitometry shown in (F) (data are mean ± SEM Figures 2F and 2G ). Both ligands were analyzed on the same gel, which revealed that, although there was no difference in the amount of G protein recruited ( Figure 2G , E max not significantly different), the hCT-occupied complex was disrupted by GTP at $10-fold lower GTP concentration than for sCT-occupied complexes ( Figures 2F and 2G ). Thermodynamically, binding of GTP to disrupt the ternary complex must be the same if the target (G protein) conformation is the same. As this differs for the two ligand-occupied complexes upon equivalent levels of G protein recruitment, it is indicative of a ligand-specific conformational difference in the recruited G protein. To test this model, we used bioluminescent resonance energy transfer (BRET) to measure rearrangement between G g , N-terminally labeled with Venus (G g :Venus), and G as with Rluc8 inserted at position 72 (G as 72 :Rluc8) ( Figure 3A ). G as
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:Rluc8 coupled to both CTR and adenylate cyclase with sCT or hCT potencies similar to wildtype G as , when transfected into cells genetically engineered to lack G as (HEK293A DG as , see STAR Methods; Schrage et al., 2015; and Figure S3A ) and responded to agonist stimulation in COS7 cells in live-cell BRET experiments ( Figure S3C ).
We performed BRET assays on washed membrane preparations in which the nucleotide concentration could be controlled. At high agonist concentrations (100 nM), we observed a rapid and sustained increase in BRET ratio ( Figure 3B ) with a greater magnitude apparent in the presence of sCT, consistent with a different conformational rearrangement of the G protein in the presence of sCT versus hCT. The release of G protein (and consequent rearrangement of the G a and G g subunits) from agonist-receptor complex requires binding of GTP to the receptor-bound nucleotide-free G protein. The addition of 300 mM GTP caused a rapid decrease in BRET signal. This decrease in BRET could be reversed by addition of high concentrations of agonist (Figures 3C and S3B) . We interpreted these ratio changes as a conformation shift from the apo to the nucleotide-bound form of the G g2 Venus:G as 72 Rluc8:G b1 hetero-trimer, consistent with previous reports of subunit rearrangement (Bü nemann et al., 2003; Galé s et al., 2006) . Supporting this model of subunit rearrangement, subsequent agonist addition led to a BRET increase above that of vehicle ( Figures 3C and S3B ). The rate of change in BRET signal following addition of 100 nM ligand was significantly faster (p < 0.0001) for sCT compared to hCT ( Figure 3D ), which we believe to be driven principally by the rate of agonist binding. In contrast, at approximate EC 50 concentrations, the rate of change in BRET was significantly faster for hCT compared to sCT (p = 0.0007) ( Figure 3E ). These data are inconsistent with a model in which increased efficacy is merely driven by increased transducer (i.e., G protein) affinity.
To further evaluate the differences in agonist-induced changes to G protein BRET, concentration-dependent timecourse assays were performed ( Figure S3D ), and normalized area under curve (AUC) was used to plot concentration response curves ( Figure 3F ). The potency for driving conformational rearrangement was lower for hCT compared with sCT ( Figure 3F ), consistent with the lower potency of hCT to induce ternary complex formation by native PAGE ( Figures 1C and 1D ). The maxima of the agonist concentration response curves were also significantly different by AUC (p < 0.0001 Figure 3F ) with hCT showing a lower maximum, supportive of different G protein hetero-trimer conformation in the agonist:receptor:G protein complex. The saturable and significant difference in the E max for this signal is consistent with different receptor-bound G protein states for these agonists (see time courses in Figure S3D ). This finding is in contrast to previous reports that activation of the same hetero-trimeric G protein complex by different receptors results in similar rearrangements (Galé s et al., 2006) . While the assay design should ensure full occupancy of the agonist receptor complex by G protein at saturating concentrations of ligand (e.g., Figure 2B ), we directly tested whether there is an agonist-dependent difference in receptor-bound G protein conformation using in-gel FRET by native PAGE. HEK293A DG as stably expressing CTR were transiently transfected with two different G protein FRET pairs using myristoylationpositive G as , with the fluorescent protein inserted at position 72 and N-terminally tagged G g2 ( Myr+ G as 72 -mCherry:G g2 -Venus or Myr+ G as
-Venus:G g2 -mCherry) and used to prepare washed membranes. Using saturating ligand concentrations, the in-gel fluorescence of the receptor-bound G protein hetero-trimer (arrows, Figure 3H ) was directly quantitated. Consistent with the native PAGE experiments in Figure 2 , equivalent levels of G protein were recruited to the hCT-and sCT-induced complexes as determined by direct excitation of the acceptor (G as -mCherry [circles] or G g2 -mCherry [squares]; Figure 3I ). In contrast, a small and significant difference in FRET between the G as and G g2 was observed between the agonist:receptor:G protein complexes with the hCT-bound complex exhibiting a lower FRET signal than the equivalent sCT-occupied complex ( Figure 3J ). This provides corroborating evidence of a difference in conformational rearrangement of the hetero-trimeric G protein in the sCT-versus hCT-occupied complexes.
To accommodate these data, the agonist-dependent receptor-bound G protein state needs to be more sensitive to GTP concentration for the more efficacious agonist, hCT, allowing for faster G protein turnover and more effective activation of adenylate cyclase. In a cellular context, GTP is present in the 200-to 400-mM range; we therefore performed BRET on extensively washed membranes containing G g :Venus/G aS 72 Rluc8 pair with the addition of GTP prior to agonist stimulation (Figures 3G and S3E) . We observed a significant reduction in EC 50 for ligandinduced BRET for hCT in the presence of GTP, but not for sCT. This is consistent with a greater sensitivity of the hCT ternary complex to GTP in native PAGE (Figures 2F and 2G) . Collectively, these data support that the hCT-occupied ternary complex has a different receptor-bound G protein conformation that is more sensitive to disruption by GTP.
To correlate the differences in GTP sensitivity from native PAGE ( Figures 2F and 2G ) and G protein BRET ( Figure 3G ) with the apparent conformational differences by BRET (e.g., Figure 3F) and in-gel FRET by Native PAGE ( Figure 3J ), we measured the rate of association of GTP to G as in pre-formed ternary complex. HEK293A DG as stably expressing CTR were transiently transfected with Myr+ G as
-mCherry and used to prepare washed membranes. These were pre-incubated with saturating concentrations of either hCT or sCT before mixing with 30 nM of ATTO488-g-(6-Aminohexyl)-GTP and the rate of association measured by FRET transfer between GTP and G as . The fitted rate was significantly faster in the presence of hCT ( Figure 3K ). The log EC 50 values for ligand-induced changes in BRET are À8.30 ± 0.08 for hCT and À8.94 ± 0.08 for sCT (n = 9, F test, p value for different EC 50 for ligand-induced change in BRET < 0.0001) with AUC top of 744 ± 24 for hCT and 900 ± 22 for hCT (n = 9 F test, *p value for different top for ligand-induced change in BRET < 0.0001, data are presented as mean ± SEM). (G) Log EC 50 values for ligand-induced change in BRET in the presence of 300 mM GTP are À7.77 ± 0.17 for hCT and À8.87 ± 0.18 for sCT (n = 4, F test, p value for different EC 50 for ligand-induced change in BRET = 0.0001), with an AUC top of 304 ± 19 for hCT and 472 ± 21 for sCT (n = 4, F test, *p value for different top for ligand-induced change in BRET <0.0001, data are mean ± SEM). GTP-induced change in pEC 50 is shown in inset with a significant decrease for hCT (n = 4-9, t test, p value for different pEC 50 in the absence of GTP = 0.0069) but no change for sCT (n = 4-9, t test, p value for different pEC 50 in the absence of GTP = 0.68 :Venus/G b1 (squares) 36 hr before preparation) were either untreated or treated with (saturating) equi-occupant concentrations of hCT (1 mM) or sCT (100 nM) prior to solubilization and separation on a 6%-11% native page. The ternary complex was identified by direct in-gel fluorescence, and data are presented as individual determinations ±SEM with FRET swap shown in circles and squares and representative gel (from n = 6, each n conducted with triplicate lanes with different plasma-membrane preparations from independent transfections and different drug dilutions on different days) shown in (H). Quantified densitometry of the acceptor only channel is shown in (I), with no difference in densitometry between hCT-and sCT-induced G protein recruitment (n = 6, t test, *p value for different densitometry = 0.51). (J) Calculated net-FRET from quantified densitometry; 0.471 ± 0.007 for hCT and 0.501 ± 0.004 for sCT (n = 6, t test, *p value for different FRET = 0.0036). and for sCT is 0.97 ± 0.05 min -1 (t 1/2 $0.71 min) (n = 6, two independent transfections, six independent drug dilutions, F test, p value for different k < 0.0001). See also Figure S3 .
To exclude the possibility that these differences in apparent efficacy and G protein conformation were the result of kinetic effects due to the slow dissociation rate of sCT, chimeric peptides (Hilton et al., 2000) , as shown in Figure 4A , were generated and tested. In cAMP accumulation assays, these chimeric peptides displayed concentration response curves that overlayed with those of the parental peptides ( Figure 4B ). Association and dissociation rates were determined using kinetic competition against a fluorescently labeled antagonist ( Figure 4C ). As expected, wild-type sCT had a very slow off rate (Andreassen et al., 2014; Hilton et al., 2000) , with a T 1/2 of >40 min, whereas all chimeric peptides displayed significantly faster off rate kinetics ( Figures 4D-4I ), demonstrating that observed potencies in the cAMP assay are not correlated with peptide binding kinetics. The potency of ligands to cause changes in G protein conformation was then assessed by BRET assays, as described above ( Figures 5A-5C ). The hCT:sCT chimera, containing the amino terminal 13 amino acids of hCT and the last 19 amino acids of sCT, induced a maximal change in BRET (G protein conformational rearrangement) that was similar to that induced by hCT but significantly different from that induced by sCT. In contrast, the EC 50 was similar to that of sCT ( Figure 5D ). These data are consistent with the peptide amino terminus driving receptor activation, while the affinity for the complex is driven by interactions of the peptide C terminus with the receptor extracellular domain (Wootten et al., 2016) . Similarly, the sCT(1-16):hCT(17-32) chimera, elicited a maximal change in BRET equivalent to that of sCT, and significantly different to that of hCT, while the EC 50 of the response was intermediate between that of sCT and hCT ( Figure 5E ). Finally the sCT triple chimera, containing three amino acids from the central portion of hCT, promoted a conformational rearrangement yielding a potency and maximal effect similar to those of sCT ( Figure 5F ) in spite of its significantly faster off rate (c.f. Figures 4E with 4H) .
Collectively, these data demonstrate that cellular efficacy results from a complex interplay between G protein recruitment affinity and the subsequent G protein conformation in the ternary complex, and that this is independent of ligand dissociation rates.
CT Ligands Differentially Stabilize Receptor-G Protein Complexes at the Cell Surface
To accommodate the equivalent cellular potency of the loweraffinity agonist, hCT, with the higher-affinity agonist sCT, and taking into account the difference in GTP binding, we reasoned that the turnover of G protein at the hCT-bound receptor would be faster than that at the sCT-bound receptor. We therefore imaged fluorescent G protein mobility at the apical surface by total internal reflection (TIRF) microscopy as depicted schematically in Figure S4 . Using a fluorescently tagged sCT analog, we established that the mobility of agonist-bound CTR is limited (data not shown) at the timescale of tens-to-hundreds of milliseconds (at 20 C). We observed two distinct, mutually exclusive, distributions of fluorescently tagged G proteins (both G as and G g2 ), either rapidly mobile G proteins with latency in the evanescent field on the tens of millisecond timescale or those that remained essentially immobile over timescales in the minutes (at 20 C). Cells transiently overexpressing G g2 Venus and native G as and exhibiting rapid G protein mobility (Movie S1) were imaged. The latency of individual G g2 Venus events in the evanescent field was extracted prior to and after stimulation with saturating concentrations of agonist and fitted to an exponential decay curve. Both ligands increased the half-life of G g2 Venus at the plasma membrane, with a significantly longer (p = 0.005) half-life in the presence of sCT (24.1 ± 1.2 versus 20.8 ± 1.1 ms for hCT and 17.9 ± 0.5 ms for unstimulated at 20 C, n = 3, Figure 6A ). This is consistent with proportionately faster G protein turnover in response to hCT versus sCT. To confirm this, we also visualized the G as subunit; the biological activity of G as 72 mCherry was confirmed by transient transfection into cells genetically engineered to lack G as (see STAR Methods; Schrage et al., 2015;  and Figure S5A ). Cells transiently overexpressing G g2 :G as 72 mCherry:G b1 and exhibiting rapid G protein mobility (Movie S2) were imaged. Only sCT produced a significant increase in the latency of individual G as 72 mCherry events in the evanescent field over vehicle (p < 0.0001) ( Figure 6A and representative 3D histograms from a small subset of data in Figure 6B ). This slower G protein mobility suggests slower GTP turnover and therefore that the GTP binding step is rate limiting when sCT is bound at the receptor. These data are consistent with native PAGE, in which hCT shows greater GTP sensitivity ( Figures  2F and 2G) , and the GTP induced change in G protein BRET EC 50 for hCT and not sCT ( Figures 3F and 3G ). Importantly, they further support a model in which hCT promotes a receptor-bound G protein conformation that is less open than the sCT conformation. This results in faster GTP binding and more rapid G protein turnover ( Figure 6C ), potentially allowing more rapid signaling.
CT Ligands Display Differential cAMP Production Rates in Live Cells
To test the latter prediction, we used a cAMP biosensor to measure the rates at which cAMP accumulates in response to these ligands. At saturating concentrations, we saw no difference in the rate or magnitude of cAMP accumulation ( Figure 7A , p = 0.215), but at 10 pM we observed a significantly faster (p = 0.018) accumulation of cAMP in response to hCT compared with sCT ( Figure 7B ). This was confirmed in a cell line that endogenously expresses CTR ( Figures 7C and 7D ) and supports our model ( Figure 6C ) in which the hCT-occupied CTR is capable of promoting more G protein activation per time compared with the sCT-occupied receptor.
DISCUSSION
Differential efficacy at GPCRs has already been exploited clinically with the use of partial agonists, for example, at adrenergic and opioid receptors (Cowan, 2003; Lipworth and Grove, 1997) . In spite of this, and the emergence of biased agonism as another means to tailor the clinical efficacy of drugs, there are few data that address the underlying molecular basis of differential efficacy. There is now a broad appreciation that different ligands acting at a single GPCR can alter the sampling of the conformational landscape explored by the GPCR (Deupi and Kobilka, 2010; Kim et al., 2013; Mary et al., 2012; Nygaard et al., 2013; Wacker et al., 2013; Wootten et al., 2013) . In general, it is thought that the consequence of ligand-dependent conformational selection is to alter the affinity of the receptor for particular transducers and thus alter signaling efficacy and/or bias. Although distinct G protein conformations linked to individual receptor complexes have been alluded to (Seifert et al., 1999 (Seifert et al., , 2001 , collectively, our work provides evidence of ligand-dependent ternary complexes controlling guanine nucleotide exchange, via promotion of distinct changes in G protein conformation.
We were able to show that binding of the high-affinity ligand, sCT, results in a ternary complex that has a lower tendency to dissociate in the presence of GTP. This is analogous to the concept that a G protein that has disproportionately high affinity for a GPCR can act in a physiologically and/or clinically relevant, ''dominant-negative'' fashion (Berlot, 2002; Grishina and Berlot, 2000; Iiri et al., 1994 Iiri et al., , 1999 . We therefore argue that, as different ligands acting at the same receptor engender differences in the sampling of conformational space by the receptor, this differential sampling extends to the heterotrimeric G protein bound in the ternary complex. Distinct, ligand-dependent conformations of transducer proteins has recently been proposed for arrestins and may control secondary signaling from these key scaffolding proteins (Lee et al., 2016; Nuber et al., 2016) . Since the prime, hCT (10 nM) after 2 min of baseline data collection at 20 C. For G g2 :Venus residency three independent experiments were performed with three to five different cell areas imaged with at least 3,000 spots of two or more frames per ligand per experiment (total of 11 cells per ligand). Spot sizes were not significantly different between hCT-and sCT-treated cells. For G as
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:mCherry residency, four independent experiments were performed with three different cell areas imaged with at least 3,000 spots of two or more frames per ligand per experiment (total of 12 cells per ligand). G protein latency in the TIRF field was fitted to an exponential decay curve and derived half-lives plotted (mean ± SEM p value for difference between unstimulated and ligand-induced decay rate of G g2 :Venus <0.0001 (**) and for difference between sCT and hCT = 0.0046 (*), one-way ANOVA (n = 3, unstimulated k = 38.3 ± 1.1, hCT k = 33.0 ± 1.9 and sCT k = 28.5 ± 0.6), p value for difference between unstimulated sCT decay rate of G as 72 :mCherry < 0.0001 (**) no significant difference between unstimulated and hCT (ns), one-way ANOVA (n = 4, unstimulated k = 39.2 ± 0.5, hCT k = 38.3 ± 0.5 and sCT k = 30.7 ± 0.6).
(B) The residence time of 625 representative spots (of >10,000 of two or more frames) was plotted in 2D with the length of residence plotted in the z dimension (as shown on scale). (C) Cartoon indicating the relative efficacy of sCT (orange) compared with hCT (blue) in which the rate-limiting step for agonist-induced G protein activation is GTP association to the receptor-bound G protein complex. The rate at which this occurs is faster in the presence of hCT allowing for quantitatively more G protein and adenylate cyclase activation per unit time in spite of lower receptor occupancy. See also Figure S4 and Movies S1 and S2.
orthodox, role of a ligand-bound GPCR is to accelerate the rate of nucleotide exchange at G a , we would argue that there is a fine balance between the affinity that the ligand-bound receptor has for its cognate G protein and its ability to release this G protein once nucleotide exchange has occurred. Indeed, for GPCRs that possess more than one endogenous agonist, this could provide another means by which their different physiological effects are engendered. Moreover, it provides an additional mechanism through which biased agonism, at the level of the G protein, can occur. Our work thus extends the understanding of the molecular basis of G protein-dependent efficacy.
STAR+METHODS
Detailed methods are provided in the online version of this paper and include the following: cAMP formation data were fitted using an exponential one phase model with the rate of production in response to 10 pM hCT being significantly faster than 10 pM sCT (B) (F test, p = 0.018), whereas no statistical difference in formation rate was seen at 10 nM (A) (F test, p = 0.215, n = 4, each n conducted in triplicate from independent transfections and different drug dilutions on different days; data are mean ± SEM).
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Conceptualization
(C and D) Rate of increase of intracellular cAMP as measured by a BRET cAMP sensor (CAMYEL) in CHO-K1 cells expressing endogenous CTR. cAMP formation data were fitted using an exponential one phase model with the onset of production in response to 1 nM hCT being significantly faster than 1 nM sCT (D) (F test, p < 0.0001), whereas no statistical difference in formation rate was seen at 100 nM (C) (F test, p = 0.0687, n = 3, each n conducted in triplicate on separate days with separate drug dilutions; data are mean ± SEM). See also Figure S5 .
receptor signaling by salmon, but not human calcitonin, reveals ligand bias. 
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EXPERIMENTAL MODEL AND SUBJECT DETAILS Cell Lines COS-7 cells (ATCC CRL-1651)
A COS-7 cell line stably transfected with pEF-IRESpuro6 (adapted from (Hobbs et al., 1998)) expression vector containing cMyc tagged hCTRaLeu (Andreassen et al., 2014) was generated as follows: A polyclonal population was selected (2mg/mL puromycin) and FACS sorted using 9E10 (anti-cMyc, produced in-house) and goat anti-mouse AF647 secondary (Life technologies). A corresponding control cell line was generated in parallel. Cell surface receptor expression was determined to be 1.2 ± 0.7 3 10 5 sites per cell, by whole cell saturation binding. Cells were maintained in DMEM (Life-technologies) with 2mg/mL puromycin (Invivogen) and 5% FBS. HEK293A with CRISPR deletion of GNAS (G as ) and GNAL (G olf ) were generated by CRISPR in the same manner as GNAQ/GNA11 disruption in Schrage et al., 2015 (Schrage et al., 2015 and successful introduction of null mutations was confirmed by DNA sequencing, western blot and functional assays. This cell line is referred to as HEK293A delG as (E.T. van der Westhuizen, W. Stallaert, A.-M. Schö negge, B. Plouffe, M. Hogue, A.I., S. Ishida, J. Aoki, and M. Bouvier, unpublished data). These were maintained in DMEM supplemented with 5% FBS.
A HEK293A delG as cell line stably transfected with pEF-IRESpuro6 (adapted from (Hobbs et al., 1998) ) expression vector containing cMyc tagged hCTRaLeu (Andreassen et al., 2014) was generated as follows: A polyclonal population was selected (10mg/mL puromycin) and receptor expression confirmed by flow cytometry and activity confirmed using a cAMP accumulation assay with transient transfection of wild-type G as .
METHOD DETAILS
Fluorescently labeled peptides K11R, Q14K, K18R substituted versions of sCT and sCT8-32 were purchased from Mimotopes. sCT8-32 was labeled with a 3-fold molar excess of AF568 succinimidyl NHS ester (Life technologies) at pH 8.3 and free dye removed using a 3 kDa molecular weight cut off centrifugal concentrator (Amicon). Labeled peptide was separated from unlabelled peptide by reverse phase HPLC and buffer exchanged into PBS before storing at À80 C. sCT was labeled with a 3-fold molar excess of AF647 succinimidyl NHS ester (Life technologies) at pH 8.3 and free dye removed using a 3 kDa molecular weight cut off centrifugal concentrator (Amicon). The degree of labeling was assessed using a Nanodrop (Thermo Scientific) and confirmed to be 1:1. The peptide ligands were then tested for receptor binding by flow cytometry and confocal microscopy and agonist activity confirmed in a cAMP accumulation assay.
Cell Culture
Transient transfections for live cell BRET, cAMP assays in HEK293A and preparation of membranes for membrane BRET assay were performed with PEI (Verzijl et al., 2008) . Linear PEI (m.w. 25000, Polysciences) was prepared in advance at 1mg/mL in sterile 150mM NaCl and the pH adjusted to 7.0. DNA was diluted to 0.02mg/mL in sterile 150mM NaCl and PEI diluted to 0.12mg/mL in sterile 150mM NaCl for a 1:6 ratio. These dilutions were immediately mixed and incubated for 10 min at room temperature before being added dropwise to the adherent cells in fresh media. DNA was added proportional to the area of cells being transfected at a concentration of 0.066mg/cm 2 . Transient transfections for live cell imaging were performed according to manufacturers instructions using Lipofectamine-2000 (Life technologies).
CTR and G protein expression and purification from insect cells
The human calcitonin receptor (hCTR) was cloned into pFastBac1 vector to give a receptor containing an N-terminal Flag epitope and a C-terminal 8x histidine tag. hCTR, human G as short, His 6 -bovine G b1 and G g2 were expressed in HighFive insect cells grown in ESF 921 serum free media (Expression Systems). Culture were grown to a density of 4 million cells per ml and then infected with 3 virus' each containing the gene for hCTR, human Gas short and dual vector of His 6 -bovine Gb 1 and Gg 2 . Cultures were grown at 27 C and harvested by centrifugation 48 hr post infection.
Cells were suspended in 20mM HEPES (pH 7.4), 50mM NaCl, 2mM MgCl 2 supplemented with cOmplete Protease Inhibitor Cocktail tablets (Roche) 1 mM salmon calcitonin, nanobody 35 (10 mg/mL) and Apyrase (25mU/mL, NEB). The complex was solubilised by 0.5% (w/v) MNG (NG-310, Anatrace) supplemented with 0.03% (w/v) cholesteryl hemisuccinate for 1 hr at 4 C. Insoluble material was removed by centrifugation and the solubilised complex were immobilised by batch binding to M1 Flag affinity resin. The resin was packed into a glass column and washed with 20mM HEPES (pH 7.4), 100mM NaCl, 2mM MgCl 2 , 3mM CaCl 2 , 100nM salmon calcitonin, 0.01% (w/v) MNG and 0.006% (w/v) cholesteryl hemisuccinate before bound material was eluted in buffer containing 5mM EDTA and 0.1mg/mL FLAG peptide. The complex was then concentrated using a Amicon Ultra Centrifugal Filters (MWCO 100 kDa) and subjected to size exclusion chromatography on a Superose 6 10/300 Increase column (GE Healthcare) in a buffer of 20mM HEPES (pH 7.4), 100mM NaCl, 2mM MgCl 2 , 100nM salmon calcitonin or 100nM human calcitonin, 0.01% (w/v) MNG and 0.006% (w/v) cholesterol hemisuccinate.
cAMP accumulation assay cAMP assays were performed as follows: complete media was replaced with phenol red free DMEM with 1mM IBMX (3-isobutyl-1-methylxanthine) and 0.1% BSA and incubated for 30 min. Cells were treated with ligands for 30 min prior to measurement of cAMP using a SureFire alphascreen cAMP kit (PerkinElmer) or Lance TR-FRET cAMP kit (PerkinElmer). All data were interpolated to actual cAMP concentration using an internal cAMP standard then normalized to the maximum forskolin or salmon calcitonin response.
Competition fluorescent binding assay Cells were plated in 96 well black CulturPlate (Perkin Elmer) at 10,000 cells per well 8 hr prior to assay. Media was replaced with ice cold DMEM with 0.1% BSA and 10nM of antagonist sCT8-32:AF568 competed against either hCT or sCT on whole cells at 4 C overnight. Cells were washed 3 times quickly with ice-cold DMEM/0.1% BSA and sCT8-32:AF568 fluorescence measured in a Pherastar (BMG Labtech).
The equilibrium constant for sCT8-32:AF568 was determined using saturation binding on whole cells at 4 C overnight in phenol red free DMEM with 0.1% BSA with non-specific determined on control cells. Cells were washed 3 times quickly with ice-cold DMEM/0.1% BSA and sCT8-32:AF568 fluorescence measured in a Pherastar (BMG Labtech).
Membrane equilibrium competition fluorescent binding assays were performed with crude plasma membrane preparations (below). Binding to membranes was performed in a final volume of 200mL in fluorescent ligand binding buffer (150 mM NaCl / 2.6 mM KCl / 1.18 mM MgCl 2 / 0.05% BSA / 1 mM DTT / 0.1 mM PMSF / 1:1000 protease inhibitor cocktail (P8340, Sigma) / 10 mM HEPES [pH 7.4]) in 96 well, black polypropylene round bottom plates (Corning) and measured homogeneously using fluorescence anisotropy in a Pherastar (BMG Labtech) after overnight incubation at 4 C.
Kinetic ligand binding
Membrane kinetic and kinetic competition fluorescent ligand binding assays were performed with crude plasma membrane preparations (below). Binding to membranes was performed in a final volume of 250mL in fluorescent ligand binding buffer (150 mM NaCl / 2.6 mM KCl / 1.18 mM MgCl 2 / 0.05% BSA / 1 mM DTT / 0.1 mM PMSF / 1:1000 protease inhibitor cocktail (P8340, Sigma) /10 mM HEPES [pH 7.4]) in 96 well, black polypropylene round bottom plates (Corning) and measured homogeneously using fluorescence anisotropy in a Pherastar (BMG Labtech) at 30 C with 4 measurements per well per minute. For all experiments crude plasma membrane was titrated to reduce maximum FP signal to % 30 mP to minimize the effects of ligand depletion. For association:dissocitation experiments baseline FP signal was measured with10nM sCT8-32:AF568 followed by addition of membranes for association then 31.6mM unlabelled sCT8-32 for dissociation. For kinetic competition baseline FP signal was measured with10nM sCT8-32:AF568 and indicated concentrations of CTR agonists followed by addition of membranes and measurement for 60 min.
Membrane preparations
Crude membranes were prepared by harvesting cells ($1.5 g packed volume) into 17 ml membrane preparation buffer (20 mM BisTris [pH 7.4] / 50 mM NaCl / 1 mM MgCl 2 / 1:1000 P8340 (protease inhibitor cocktail, Sigma) / 1 mM DTT / 0.1 mM PMSF) followed by homogenization with a polytron homogenizer at 4 C. The homogenate was then centrifuged for 10 min at 700 g. The supernatant was centrifuged at 100,000 3 g for 30 min at 4 C. The pellet was washed by re-suspension in 17mL membrane preparation buffer and recentrifuged at 100,000 3 g for 30 min at 4 C. The final pellet, containing cell membranes was resuspended in 800 ml membrane preparation buffer and stored at À80 C.
Crude plasma membranes were prepared by harvesting cells ($1.5 g packed volume) into 10 ml membrane preparation buffer followed by homogenization with a polytron homogenizer at 4 C. The homogenate was loaded onto a stepped sucrose gradient (40% / 10% / homogenate) and centrifuged at 100,000 3 g for 2 hr 30 min at 4 C. The 40% / 10% interface ($1.5mL) was collected and diluted to 17 ml with membrane preparation buffer followed by centrifugation at 100,000 3 g for 30 min at 4 C. The final pellet, containing crude plasma membranes was resuspended in $350mL membrane preparation buffer and stored at À80 C. Enriched plasma membranes were prepared by harvesting cells ($1.5 g packed volume) into 5 ml membrane preparation buffer followed by homogenization with a polytron homogenizer at 4 C. The homogenate was loaded onto a stepped sucrose gradient (40% / 35% / 22.5% / 10% / homogenate) and centrifuged at 100,000 3 g for 2 hr 30 min at 4 C. The 22.5% / 10% interface ($1.5mL) was collected and diluted to 17 ml with membrane preparation buffer followed by centrifugation at 100,000 3 g for 30 min at 4 C. The final pellet, containing enriched plasma membranes was resuspended in $250mL membrane preparation buffer and stored at À80 C.
Native PAGE In vitro transformation; either 20mg (all COS-7/CTR experiments) or 40mg (all HEK293A DG as / CTR experiments) of purified plasma membrane was added to 1mL of plasma membrane preparation buffer containing the indicated concentrations of agonist and nucleotide, incubated for 30 min at 30 C before centrifugation at 20,000 3 g at 4 C. Membrane pellets were then solubilised in 15 ml of plasma membrane preparation buffer containing either 2% digitonin (Serva) or 1% MNG (Affimetrix)/ 0.1% CHS (Affimetrix) and 10% glycerol for 10 min at 4 C. For antibody shift experiments FAbs (9E10, anti-cMyc (in-house) and 1H10, anti-CTR (Welcome Receptor Antibodies (Wookey et al., 2012))) were added at this point and incubated at 4 C for 1 hr. Insoluble material was pelleted by centrifugation at 20,000 3 g for 5 min at 4 C. The methods of Wittig et al. were adapted for blue native PAGE (Wittig et al., 2006) and high resolution clear native PAGE (Wittig et al., 2007) . For blue native PAGE samples were then directly loaded. For high-resolution clear native PAGE ponceau S (Serva) was added to a final concentration of 0.1% w/v. High resolution native PAGE, 6%-11% and 4%-13.5% linear gradient gels were prepared using a BisTris / Tricine / 6-amino caproic acid buffering system. Electrophoresis was performed at 4 C at pH 7.4. For blue native PAGE the cathode buffer contained 0.02% Coomassie G-250; for high-resolution clear native PAGE there was 0.02%MNG/0.002%CHS (Affimetrix) in the cathode buffer.
For blue native PAGE transfers were performed using a BisTris / Tricine buffer at pH 7.4, whereas, a Tris / Acetate buffer at pH 8.6 for transfer from high-resolution clear native PAGE.
For in gel fluorescence and FRET measurements between G as and G g2 HEK293A D G as cells stably expressing CTR were transfected with 1:1:1 ratios of G g2 :Venus / Mry+ G as
72
:mCherry / G b1 OR G g2 :mCherry / Mry+ G as 72 :Venus / G b1 36 hr prior to harvesting and preparation of crude plasma membranes (above). In vitro transformation with agonists was performed as described above. Gels were immediately imaged post electrophoresis using a Typhoon multimode imager (GE Healthcare life sciences). The lane order was randomized between experiments to eliminate systematic errors that may be introduced while imaging. The donor (Venus) channel was imaged using the 488 laser and 520/40 emission filter, acceptor with the 532 laser and 610/30 emission filter while the FRET signal was captured using the 488 laser and 610/30 emission filter.
Immunoblotting was performed using anti-cMyc antibody (9E10 (IgG 1 ), in house), anti-CTR (1H10 (IgG 2a ) Welcome Receptor Antibodies), anti-G as SC383 (Santa-Cruz) primary antibodies and highly cross absorbed goat anti-mouse AF647, goat anti-rabbit AF532, goat anti-mouse IgG1 AF568 and goat anti-mouse IgG2a AF633 secondaries (Life-Technologies). Transfers were performed as described above, overnight at 4 C at 20V to low fluorescence PVDF membrane (BioRad). Transfers from blue native PAGE were first destained with methanol then rinsed with MQ H 2 O. Transfers were stained with 0.2% Ponceau / 3% trichloroacetic acid in MQ H 2 O and molecular weight standards marked with a pencil. Membranes were then destained with PBS/0.05% Tween20 and blocked for 1 hr with 5% BSA in PBS/0.05% Tween20. All primary antibodies were diluted to a final concentration of 1mg/mL in PBS with 1% BSA, 0.05% Tween20 and 0.02% sodium azide. Membranes were incubated either overnight at 4 C or room temperature for 2 hr with primary antibody dilutions. Membranes were then washed 3 times for 5 min each in PBS/0.05% Tween20. All secondary antibodies were diluted to 1mg/mL in PBS/0.05% Tween20. Membranes were incubated in secondary antibody mixtures for 90 min at room temperature. Membranes were then washed 3 times for 5 min each in PBS/0.05% Tween20 prior to imaging. All images were captured using a Typhoon multimode imager (GE Healthcare life sciences).
G protein BRET Live cell BRET: COS-7 cells stably expressing CTR were transfected with 2:1:2 ratios of G g2 :Venus / G as 72 :Rluc8 / G b1 16 hr prior to assay. Media was replaced with DMEM/0.05%BSA and cells equilibrated for 30 min. 10 min prior to assay coelantrazine h was added to a final concentration of 5mM. Baseline measurements were taken for 1 min prior to addition of vehicle or agonists and reading for a further 9 min. All assays were performed in a final volume of 200 ml and BRET measurements were made in a Pherastar. BRET on crude membranes. COS-7 cells stably expressing CTR were transfected with 2:1:2 ratios of G g2 :Venus / G as 72 :Rluc8 / G b1 16 hr prior to harvesting and preparation of crude membranes (above). Membranes were added at 20 mg per well in a modified HBSS buffer consisting of HBSS with 10 mM HEPES (final pH 7.4) / 1mM DTT / 0.1mM PMSF / 1:1000 P8340 and 0.01%BSA at 37 C. Coelantrazine h (Nanolight) was added to a final concentration of 5mM and baseline measurements taken for 1 min prior to the addition of vehicle or GTP. A further 1 min of measurements were taken, followed by addition of vehicle or agonist and reading for a further 15 min. All assays were performed in a final volume of 250 ml and measured in a Pherastar.
GTP association HEK293A D G as cells stably expressing CTR were transfected with 1:1:1 ratios of G g2 / Mry+ G as 72 :mCherry / G b1 16 hr prior to harvesting and preparation of crude membranes (above). 100mg of crude membrane was diluted to 50mL in membrane preparation buffer containing an additional 10mM MgCl 2 , 500mM ATP, 1mM DTT, 1:1000 P8340 and 0.05% BSA and 1mM of either hCT or sCT prior to incubation at 30 C for 20 min. This was then allowed to cool to room temperature (25 C) for approximately 5 min. 50mL aliquots of membrane preparation buffer containing an additional 10mM MgCl 2 , 500mM ATP, 1mM DTT, 1:1000 P8340 and 0.05% BSA and 60nM ATTO488-g-(6-Aminohexyl)-GTP buffer were transferred to 96 well, black polypropylene round bottom plates (Corning) and allowed to equilibrate to 25 C in a Pheratar (BMG Labtech). Binding was initiated by addition of pre-equilibrated membranes and FRET measured homogeneously using a Pherastar (BMG Labtech) at 25 C with 6 measurements per well per minute.
G protein residency COS-7 cells stably expressing CTR were plated onto fibronectin (Sigma) coated transwell inserts (Falcon) 24 hr prior to assay. 16 hr prior to assay cells were transiently transfected either with G g2 :Venus OR 1:1:1 ratio of G g2 / G as
:mCherry / G b1 . On the day of assay media was replaced with room temp (20 C) phenol red free DMEM with 0.05% BSA. The transwell insert was then removed and the PET membrane carefully removed with a scalpel blade. This was placed apical side down on a fluorodish (Precision World Instruments) and a custom manufactured, food grade stainless steel weight added to the periphery, all in room temp (20 C) phenol red free DMEM with 0.05% BSA. Apical cell regions were imaged with a Leica TIRF microscope with a 160x (Plan Apo), 1.47NA oil objective at 33 frames per second (G g2 :Venus) or 40 frames a second (G as 72 :mCherry). An image sequence of (typically) 2 min was captured prior to the addition of agonist followed by 2 -5 min of image acquisition.
Modeling G protein rearrangement
The crystal structure of the b 2 adrenergic receptor in complex with G as b 1 g 2 (PDB: 3SN6) was used as a template, the crystal structure of Rluc8 (PDB: 2SPSD) was positioned to align its N-and C-terminal amino acids with the unresolved loop of the G as chain where the genetic insertion was made and the crystal structure of eYFP (PDB: 3V3D) placed at the C-terminus of the Gg 2 chain. The crystal structure of the GDP bound conformation of G as (PDB: 1AZT) was aligned to the ternary complex structure by RMSD minimization of the RAS-like domain of the ternary bound and GDP bound subunit; the ternary bound G 0 G as was thus replaced with inactive G as and Rluc8 (PDB: 2SPSD) was positioned to align its N-and C-terminal amino acids with the unresolved loop of the G as chain where the genetic insertion was made and the crystal structure of eYFP (PDB: 3V3D) placed at the C-terminus of the Gg 2 chain. Amino acids 156-171 of Rluc8 are highlighted in magenta to show the rotation and translation of Rluc8 necessary to accommodate the open versus closed state of G as .
BRET CAMYEL assay COS-7 cells were simultaneously transfected using linear polyethyleneimine (Verzijl et al., 2008) 24 hr prior to assay. Cells (approximately 1.8x10 5 ) were mixed with 300 ng CTR DNA and 500 ng/well BRET cAMP biosensor DNA (CAMYEL (Jiang et al., 2007) ) at a 1:6 DNA to PEI ratio, prior to seeding into 16 wells of a white opaque 96-well plate in 5% FBS (v/v) DMEM with penicillin/streptomycin. Cells were washed with Hank's balanced salt solution (HBSS), and then equilibrated in HBSS with 0.1% (w/v) BSA at 37 C for 30 min prior to assay. RLuc luminescence and YFP fluorescence were measured using a Pherastar microplate reader (BMG LabTech) following addition of the RLuc substrate, coelenterazine h (Nanolight, 3 mM, 30 min prior to read). The baseline BRET ratio was measured for 1 min. Following automated addition of vehicle, hCT or sCT, the stimulated BRET ratio was measured for 5 min, prior to the manual addition of a positive control cocktail (10 mM forskolin, 100 mM 3-isobutyl-1-methylxanthine [IBMX] and 100 nM prostaglandin E 1 ) to confirm sub-saturating stimulation by hCT and sCT (see Figures S5B and S5C) . The change in BRET in response to the positive control cocktail was measured for 4 min. Measurements were made in duplicate, every 4 s.
Increases in cAMP were analyzed by determining the BRET signal as a ratio of the light emitted at 465-505 nm (RLuc) to the light emitted at 505-555 nm (YFP). For each well, the BRET data were expressed as the change in BRET signal relative to the average baseline and positive control responses in the first and last min of the time course, respectively ([BRET signal -average BRET baseline]/maximum BRET signal; BRET/BRET Max ). Data were fitted to a one-phase association curve using PRISM and an extra sum-of-squares F test applied to determine whether differences in association rate existed.
QUANTIFICATION AND STATISTICAL ANALYSIS
cAMP accumulation assay analysis All data were was interpolated to actual cAMP concentration by fitting and internal standard of known cAMP concentrations to a 3 parameter logistic curve in PRISM (Graphpad) and then normalized to the maximum forskolin or salmon calcitonin response. This data were analyzed using a biphasic, 4-parameter concentration response equation in PRISM (Graphpad) and an extra sumof-squares F test applied to determine whether differences in E max and EC 50 existed.
Ligand binding analysis
The equilibrium constant for sCT8-32:AF568 was calculated using a one-site fit using PRISM (Graphpad) with non-specific binding determined by binding to parental (untransfected) cells.
Whole cell and membrane equilibrium competition binding was analyzed using a single phase or biphasic (chosen on the basis of an extra sum-of-squares F test comparison between models), 4-parameter competition equation in PRISM (Graphpad) with equilibrium constant of the probe determined by saturation binding (above) and an extra sum-of-squares F test applied to determine whether differences in K i existed.
Kinetic parameters for sCT8-32:AF568 were calculated in PRISM (Graphpad) using an association then dissociation model to derive K on and K off from direct measurements of K obs and K off .
Kinetic competition parameters for all unlabelled ligands were calculated using the K on and K off calculated for sCT8-32:AF568 by fitting data from multiple concentrations of unlabelled competitor to a model of competitive binding kinetics using PRISM (Graphpad) (see (Motulsky and Mahan, 1984) ).
Analysis of Native PAGE For immunoblotting of native PAGE densitometry was performed using standard methods with the Fiji distribution of ImageJ (Schindelin et al., 2012) and data analyzed using a 3-parameter concentration response equation in PRISM (Graphpad) and an extra sumof-squares F test applied to determine whether differences in EC 50 existed.
For in gel fluorescence and FRET a script was written to average the densitometry from the 3 control lanes and subtract this average from the agonist lanes. The AUC for the receptor recruited G protein band was quantified for all ligand lanes in donor, acceptor and FRET channels. To allow comparison across experiments the lane with the largest acceptor AUC value (regardless of which ligand) was used to normalize the AUC for all lanes. This lane was also then used to normalize the remaining 2 channels. The net FRET was calculated as follows: FRET / (donor + acceptor). An unpaired t test was used to determine whether differences in acceptor of FRET signal differed between ligand treatments.
G protein BRET analysis
For rate calculations data were fitted to a one-phase association curve in PRISM (Graphpad) and an extra sum-of-squares F test applied to determine whether differences in association rate existed. For EC 50 and E max determinations AUC was used to fit 3-parameter concentration response curves using PRISM (Graphpad) on individual experiments. The derived EC 50 and E max values were then used to perform paired t tests to determine whether differences existed and mean values used to generate curve fits shown in figures.
GTP association analysis
Rate data were fitted to a one-phase association curve in PRISM (Graphpad) and an extra sum-of-squares F test applied to determine whether differences in association rate existed.
G protein residency analysis
Residency times were measured using the Fiji distribution of ImageJ (Schindelin et al., 2012) . A script was developed to apply the following analysis to all image sequences: A Gaussian blur (1 sigma) was applied to the time series. The centroid of the local spot maxima was detected using the Find maxima command (threshold varied between 50 and 250 depending on signal strength). Binary masks of single spots were created and dilated by 2 pixels to allow robust detection of subsequent spots in the time series. Overlapping dilated spots were then assessed for how many frames they were present. This process was repeated for all detected spots in a given time series. The number of spots occurring for each frame bin (bins from 1 to 100 frames) was counted for each image sequence. Spots occurring for a single frame only were discarded to eliminate sampling error. The sum of the remaining spots was used to convert the absolute number per bin to a percentage. Percentages from a particular experiment were averaged and the averages from all experiments used to derive an exponential decay curve to estimate residency time. Each experiment was performed on 3 separate days (n = 3), on each day at least 2 separate image sequences for an unstimulated, hCT and sCT stimulated cell was captured and only image sequences containing > 3,000 events of longer than 2 frames were used for analysis. For 3D residency plots the residency of 625 spots from representative image sequences were plotted as a 2D histograms.
DATA AND SOFTWARE AVAILABILITY TIRF residency script
The custom script (http://dx.doi.org/10.4225/03/57C81DC64E72B) was written to measure the time a given spot was present in the TIRF field. This is achieved by extracting the individual spots as single binary points and then measuring how many frames each one is present for before the signal decreases to background.
In gel FRET quantitation script
The custom script (http://dx.doi.org/10.4225/03/57C821AE2C2DDc) was written to allow automated and unbiased background subtraction and quantitation of the fluorescence densitometry.
